Hemostemix (CVE:HEM) Stock Price Up 38.1% – What’s Next?

Hemostemix Inc. (CVE:HEM) traded up 38.1% on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. 605,625 shares changed hands during mid-day trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.

Hemostemix Trading Up 38.1 %

The company has a 50-day moving average of C$0.09 and a 200-day moving average of C$0.07. The firm has a market capitalization of C$12.63 million, a price-to-earnings ratio of -7.25 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.